Abstract
The aim of this study is to examine the effects of treatment with varenicline, a partial agonist at the α4β2 and full agonist at the α7 nicotine acetylcholine receptor, on cognitive impairments in people with schizophrenia. In all, 120 clinically stable people with schizophrenia participated in randomized, double-blind, placebo-controlled 8-week trial. Antipsychotic and concomitant medication doses remained fixed throughout the study. Varenicline was titrated up to 1 mg twice daily for weeks 2–8. Neuropsychological, clinical, and safety assessments were administered at baseline and weeks 1, 2, 4, and 8. In the primary analyses of neurocognitive differences at week 8, no varenicline–placebo differences were significant. In secondary longitudinal analyses, varenicline improved compared with placebo on the Digital Symbol Substitution Test (p=0.013) and the Wisconsin Card Sorting Test non-perseverative errors (p=0.043). Some treatment effects were different between smokers and non-smokers. In smokers, Continuous Performance Test hit reaction time (p=0.008) and Stroop Interference (p=0.004) were reduced for varenicline compared with placebo, while there were no treatment differences in non-smokers. No significant treatment main effects or interactions were noted for total scores on the Positive and Negative Syndrome Scale or the Scale for the Assessment for Negative Symptoms. Our findings suggest beneficial effects of adjunctive varenicline treatment with antipsychotics for some cognitive impairments in people with schizophrenia. In some cases, effects of treatment varied between smokers and non-smokers. Further study is required to assess the functional significance of these changes.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Addy N, Levin ED (2002). Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. Neuropsychopharmacology 27: 534–541.
Andreasen NC (1982). Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39: 784–788.
Arthur D, Levin ED (2002). Chronic inhibition of alpha4beta2 nicotinic receptors in the ventral hippocampus of rats: impacts on memory and nicotine response. Psychopharmacology (Berl) 160: 140–145.
Barnes TR (2003). The Barnes Akathisia Rating Scale-revisited. J Psychopharmacol 17: 365–370.
Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP et al (2008). The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 33: 480–490.
Bencherif M, Schmitt JD (2002). Targeting neuronal nicotinic receptors: a path to new therapies. Curr Drug Targets CNS Neurol Disord 1: 349–357.
Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM et al (2000). Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23: 351–364.
Breslau N, Schultz LR, Johnson EO, Peterson EL, Davis GC (2005). Smoking and the risk of suicidal behavior: a prospective study of a community sample. Arch Gen Psychiatry 62: 328–334.
Coe PR, Brooks MG, Vetelino MC, Wirtz EP, Arnold J, Huang SB et al (2005). Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48: 3474–3477.
Conners CK (2004). The Continuous Performance Test (CPTII). Multi-Health Systems Inc.: North Tonawanda, New York.
Evins AE, Goff DC (2008). Varenicline treatment for smokers with schizophrenia: a case series. J Clin Psychiatry 69: 1016.
Freedman R (2007). Exacerbation of schizophrenia by varenicline. Am J Psychiatry 164: 1269.
George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper WT et al (2002). Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 26: 75–85.
Golden CJ, White L, Combs T, Morgan M, McLane D (1999). WMS-R and MAS correlations in a neuropsychological population. Arch Clin Neuropsychol 14: 265–271.
Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB et al (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296: 47–55.
Green MF (2006). Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 67 (Suppl 9): 3–8.
Guy W, Bonato RR (1970). In: Chevy Chase Md (eds). Manual for the ECDEU Assessment Battery, revised 2nd edn. National Institute of Mental Health, George Washington University. pp 12.1–12.6.
Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62.
Heaton RK, Chelune GJ, Talley JL (1993). Wisconsin Card Sorting Test, Manual. Psychological Assessment Resources: Odessa, Florida.
Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller FL et al (2011). Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry (e-pub ahead of print 1 August 2011).
Jubelt LE, Barr RS, Goff DC, Logvinenko T, Weiss AP, Evins AE (2008). Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. Psychopharmacology 199: 89–98.
Kantrowitz JT, Revheim N, Pasternak R, Silipo G, Javitt DC (2009). It's all in the cards: effect of stimulus manipulation on Wisconsin Card Sorting Test performance in schizophrenia. Psychiatry Res 168: 198–204.
Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276.
Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM et al (2004). Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 161: 985–995.
Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Dickinson D, Nelson M et al (2009). A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry 70: 518–525.
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR (2005). What does the PANSS mean? Schizophr Res 79: 231–238.
Levin ED, Bradley A, Addy N, Sigurani N (2002). Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience 109: 757–765.
Levin ED, Wilson W, Rose JE, McEvoy J (1996). Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15: 429–436.
Lezak MD (1995). Neuropsychological Assessment, 3rd edn. Oxford University Press: New York.
Loughead J, Ray R, Wileyto EP, Ruparel K, Sanborn P, Siegel S et al (2010). Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol Psychiatry 67: 715–721.
Marder SR, Fenton W (2004). Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 72: 5–9.
Marutle A, Zhang X, Court J, Piggott M, Johnson M, Perry R et al (2001). Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 22: 115–126.
Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux JP et al (2005). Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 436: 103–107.
Mihalak KB, Carroll FI, Luetje CW (2006). Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 70: 801–805.
Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC et al (2009). Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry 65: 144–149.
Poorthuis RB, Goriounova NA, Couey JJ, Mansvelder HD (2009). Nicotinic actions on neuronal networks for cognition: general principles and long-term consequences. Biochem Pharmacol 78: 668–676.
Rabin RA, Sacco KA, George TP (2009). Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking status. Schizophr Res 114: 91–97.
Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA et al (2007). Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52: 985–994.
Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S et al (2005). Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 62: 649–659.
Sergi MJ, Green MF, Widmark C, Reist C, Erhart S, Braff DL et al (2007). Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry 164: 1585–1592.
Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11–19.
Smith RC, Lindenmayer JP, Davis JM, Cornwell J, Noth K, Gupta S et al (2009). Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 110: 149–155.
US Food and Drug Administration (2008). FDA issues Public Health Advisory on Chantix. FDA News. Available at http://www.fda.gov/bbs/topics/NEWS/2008/NEW01788.html.Accessibility verified February 01, 2008.
Wechsler D (1981). Manual for the Wechsler Adult Intelligence Scale-Revised. The Psychological Corporation: San Antonio.
Woods SW (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64: 663–667.
Acknowledgements
This study was supported by a grant from the Stanley Medical Research Institute (07TGS-1051). No authors received any financial support from the pharmaceutical industry for this study. Trial Registration: Clinicaltrials.gov Identifier NCT00523445.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Neuropsychopharmacology website
Supplementary information
PowerPoint slides
Rights and permissions
About this article
Cite this article
Shim, JC., Jung, DU., Jung, SS. et al. Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial. Neuropsychopharmacol 37, 660–668 (2012). https://doi.org/10.1038/npp.2011.238
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2011.238
Keywords
This article is cited by
-
Modern synthesis of cognitive enhancers: cholinergic ligands
Russian Chemical Bulletin (2023)
-
Varenicline for cognitive impairment in people with schizophrenia: systematic review and meta-analysis
Psychopharmacology (2020)
-
Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis
npj Schizophrenia (2018)
-
Compromised neuroplasticity in cigarette smokers under nicotine withdrawal is restituted by the nicotinic α4β2-receptor partial agonist varenicline
Scientific Reports (2017)
-
Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys
Psychopharmacology (2016)
